The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Open accessAbstract
BACKGROUND: Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas. METHODS: We performed genomewide analyses of 293 lower-grade gliomas from adults, incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA expression, microRNA expression, and targeted protein expression. These data were integrated and tested for correlation with clinical outcomes. RESULTS: Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had genomic aberrations and clinical behavior strikingly similar to those found in primary glioblastoma. CONCLUSIONS: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our patient’s tumor harbored mutations in TERT, FUBP1, and CIC, which are common alterations in oligodendroglioma, but not clinically relevant [46,47].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [47]
Experimental — accuracy not yet measuredIn the citing paper
“IDH WT astrocytomas are, for the most part, highly aggressive, having a median survival of 18 mo”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“Second, predicted risks are consistent with the published expected overall survivals associated with molecular subtypes (37).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“and these have the lowest overall predicted risks consistent with overall survivals of 10+ y (37, 39).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“IDH mutant astrocytomas are another subtype with considerably better overall survival ranging from 3 to 8 y”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“In recent years, two landmark genomic studies carried out in human glioma and acute myeloid leukaemia (AML) found mutations in IDH1/2 and it is now appreciated that these enzymes (which drive elevated production of D-2-HG) are the most frequently mutated metabolic genes in human cancer112-114.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Glioma Groups Based on 1p/19q, IDH , and TERT Promoter Mutations in Tumors
Eckel‐Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,981
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Parker BC, 2013, J Clin Invest, 123, 855
Cited by
Sorted by citations
Items 301–400 of 1,002
Wijnenga, M. M. J., Dubbink, H. J., French, P. J., Synhaeve, N. E., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Dirven, C. M. F., Vincent, A. J. P. E., & van den Bent, M. J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1781-z · Cited by 103
Prognosis Analysis and Validation of m6A Signature and Tumor Immune Microenvironment in Glioma
Lin, S., Xu, H., Zhang, A., Ni, Y., Xu, Y., Meng, T., Wang, M., & Lou, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.541401 · Cited by 103
A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes
Giachino, C., Boulay, J., Ivánek, R., Alvarado, A. G., Tostado, C., Lugert, S., Tchorz, J. S., Coban, M., Mariani, L., Bettler, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.008 · Cited by 105
Machine learning classifies cancer
Wong, D., & Yip, S. S. F. (2018) · Nature · doi:10.1038/d41586-018-02881-7 · Cited by 102
Su, C., Jiang, J., Zhang, S., Shi, J., Xu, K., Shen, N., Zhang, J., Li, L., Zhao, L., Zhang, J., et al. (2018) · European Radiology · doi:10.1007/s00330-018-5704-8 · Cited by 102
MRI Features Can Predict 1p/19q Status in Intracranial Gliomas
Lasocki, A., Gaillard, F., Gorelik, A., & Gonzales, M. F. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5572 · Cited by 101
Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression
Meisel, C. T., Porcheri, C., & Mitsiadis, T. A. (2020) · Cells · doi:10.3390/cells9081879 · Cited by 103
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
Wheeler, D. A., Takebe, N., Hinoue, T., Hoadley, K. A., Cardenas, M., Hamilton, A. M., Laird, P. W., Wang, L., Johnson, A., Dewal, N., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.015 · Cited by 103
Treatment Strategies for Low-Grade Glioma in Adults
Bush, N. A. O., & Chang, S. M. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.018622 · Cited by 106
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
Lee, Y., Koh, J., Kim, S., Won, J., Park, C., Choi, S. H., & Park, S. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0465-1 · Cited by 101
State of the Art: Machine Learning Applications in Glioma Imaging
Lotan, E., Jain, R., Razavian, N., Fatterpekar, G. M., & Lui, Y. W. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.18.20218 · Cited by 101
Patel, S. K., George, B., & Rai, V. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01177 · Cited by 102
Ferroptosis‐related gene signature predicts prognosis and immunotherapy in glioma
Wan, R., Wang, P., Xia, Q., Zhou, H., & Mao, X. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13654 · Cited by 100
Whole-genome landscape of adult T-cell leukemia/lymphoma
Kogure, Y., Kameda, T., Koya, J., Yoshimitsu, M., Nosaka, K., Yasunaga, J., Imaizumi, Y., Watanabe, M., Saito, Y., Ito, Y., et al. (2021) · Blood · doi:10.1182/blood.2021013568 · Cited by 102
Tanboon, J., Williams, E. A., & Louis, D. N. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv009 · Cited by 100
Sparse Representation-Based Radiomics for the Diagnosis of Brain Tumors
Wu, G., Chen, Y., Wang, Y., Yu, J., Lv, X., Ju, X., Shi, Z., Chen, L., & Chen, Z. (2017) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2017.2776967 · Cited by 99
The Case for a Pre-Cancer Genome Atlas (PCGA)
Campbell, J. D., Mazzilli, S. A., Reid, M. E., Dhillon, S. S., Platero, S. J., Beane, J., & Spira, A. E. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0024 · Cited by 98
Tateishi, K., Higuchi, F., Miller, J. J., Koerner, M. V. A., Lelic, N., Shankar, G. M., Tanaka, S., Fisher, D. E., Batchelor, T. T., Iafrate, A. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2263 · Cited by 100
Metabolomics Applications in Precision Medicine: An Oncological Perspective
Puchades‐Carrasco, L., & Pineda‐Lucena, A. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170707120034 · Cited by 101
Mondal, G., Lee, J. C., Ravindranathan, A., Villanueva-Meyer, J. E., Tran, Q. T., Allen, S. J., Barreto, J., Gupta, R. K., Doo, P., Ziffle, J. V., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02155-5 · Cited by 103
Signaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 105
Gliomatosis cerebri: no evidence for a separate brain tumor entity
Herrlinger, U., Jones, D., Glas, M., Hattingen, E., Gramatzki, D., Stuplich, M., Felsberg, J., Bähr, O., Gielen, G. H., Simon, M., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1495-z · Cited by 97
The genetic landscape of gliomas arising after therapeutic radiation
Lopez, G. Y., Ziffle, J. V., Onodera, C. S., Grenert, J. P., Yeh, I., Bastian, B. C., Clarke, J. L., Bush, N. A. O., Taylor, J. W., Chang, S. M., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1906-z · Cited by 96
Wu, S., Meng, J., Yu, Q., Li, P., & Fu, S. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2787-1 · Cited by 96
Current Approaches for Glioma Gene Therapy and Virotherapy
Banerjee, K., Núñez, F. J., Haase, S., McClellan, B. L., Faisal, S. M., Carney, S. V., Yü, J., Alghamri, M. S., Asad, A. S., Candia, A. J. N., et al. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.621831 · Cited by 96
Pediatric low-grade glioma: State-of-the-art and ongoing challenges
Fangusaro, J., Jones, D., Packer, R. J., Gutmann, D. H., Milde, T., Witt, O., Mueller, S., Fisher, M. J., Hansford, J. R., Tabori, U. Y., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad195 · Cited by 102
Computer-aided grading of gliomas based on local and global MRI features
Hsieh, K. L., Lo, C., & Hsiao, C.-J. (2016) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2016.10.021 · Cited by 95
Villanueva-Meyer, J. E., Wood, M. D., Choi, B. S., Mabray, M. C., Butowski, N. A., Tihan, T., & Cha, S. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.17.18457 · Cited by 95
EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC
Krishnamoorthy, G. P., Davidson, N. R., Leach, S. D., Zhao, Z., Lowe, S. W., Lee, G., Landa, I., Nagarajah, J., Saqcena, M., Singh, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0606 · Cited by 94
Chmielecki, J., Bailey, M., He, J., Elvin, J. A., Vergilio, J., Ramkissoon, S. H., Suh, J. H., Frampton, G. M., Sun, J., Morley, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1106 · Cited by 98
Brain tumor classification using the fused features extracted from expanded tumor region
Öksüz, C., Urhan, O., & Güllü, M. K. (2021) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2021.103356 · Cited by 94
Lam, K. H. B., Leon, A. J., Hui, W., Lee, S. C.-E. S., Batruch, I., Faust, K., Klekner, Á., Hutóczki, G., Koritzinsky, M., Richer, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27667-w · Cited by 97
Natsume, A., Arakawa, Y., Narita, Y., Sugiyama, K., Hata, N., Muragaki, Y., Shinojima, N., Kumabe, T., Saito, R., Motomura, K., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac155 · Cited by 93
Ren, Y., Zhang, X., Rui, W., Pang, H., Qiu, T., Wang, J., Xie, Q. R., Jin, T., Zhang, H., Chen, H., et al. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26240 · Cited by 95
Low-Grade Glioma Radiotherapy Treatment and Trials
Wang, T. J. C., & Mehta, M. P. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.08.008 · Cited by 95
The management of low-grade gliomas in adults
Morshed, R. A., Young, J. S., Hervey‐Jumper, S. L., & Berger, M. S. (2019) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.19.04701-5 · Cited by 93
Microenvironmental Heterogeneity in Brain Malignancies
Perus, L. J. M., & Walsh, L. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02294 · Cited by 96
Guo, X., Gu, L., Li, Y., Zheng, Z., Chen, W., Wang, Y., Wang, Y., Xing, H., Shi, Y., Liu, D., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200815 · Cited by 97
Understanding inherited genetic risk of adult glioma – a review
Rice, T., Lachance, D. H., Molinaro, A. M., Eckel‐Passow, J. E., Walsh, K. M., Barnholtz‐Sloan, J. S., Ostrom, Q. T., Francis, S. S., Wiemels, J. L., Jenkins, R. B., et al. (2015) · Neuro-Oncology Practice · doi:10.1093/nop/npv026 · Cited by 92
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
Chowdhury, S., Kennedy, J. J., Ivey, R. G., Murillo, O. D., Hosseini, N., Song, X., Petralia, F., Calinawan, A. P., Savage, S. R., Berry, A. B., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.004 · Cited by 95
LeBlanc, A. K., Mazcko, C. N., Brown, D. E., Koehler, J. W., Miller, A. D., Miller, C. R., Bentley, R. T., Packer, R. A., Breen, M., Boudreau, C. E., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now051 · Cited by 91
Tietze, A., Choi, C., Mickey, B., Maher, E. A., Ulhøi, B. P., Sangill, R., Lassen–Ramshad, Y., Lukacova, S., Østergaard, L., & von Öettingen, G. (2017) · Journal of neurosurgery · doi:10.3171/2016.10.jns161793 · Cited by 90
Anzalone, N., Castellano, A., Cadioli, M., Conte, G. M., Cuccarini, V., Bizzi, A., Grimaldi, M., Costa, A., Grillea, G., Vitali, P., et al. (2018) · Radiology · doi:10.1148/radiol.2017170362 · Cited by 90
Glioblastoma Therapy in the Age of Molecular Medicine
Geraldo, L. H., Garcia, C., da Fonseca, A. C. C., Dubois, L. G., Spohr, T. C. L. D. S. E., Matias, D., Magalhães, E. S. D. C., do Amaral, R. F., da Rosa, B. G., Grimaldi, I., et al. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.002 · Cited by 93
Intraoperative MRI versus 5-ALA in high-grade glioma resection: a network meta-analysis
Golub, D., Hyde, J., Dogra, S., Nicholson, J., Kirkwood, K. A., Gohel, P., Loftus, S. C., & Schwartz, T. H. (2020) · Journal of neurosurgery · doi:10.3171/2019.12.jns191203 · Cited by 91
Thomas, D. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-22-120 · Cited by 92
Ostrom, Q. T., Kinnersley, B., Wrensch, M., Eckel‐Passow, J. E., Armstrong, G., Rice, T., Chen, Y., Wiencke, J. K., Mccoy, L. S., Hansen, H. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24580-z · Cited by 93
Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma
Tomé-García, J., Erfani, P., Nudelman, G., Tsankov, A. M., Katsyv, I., Tejero, R., Zhang, B., Walsh, M. J., Friedel, R. H., Zaslavsky, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06258-2 · Cited by 91
A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma
Xie, Z., Janczyk, P. Ł., Zhang, Y., Liu, A., Shi, X., Singh, S., Facemire, L., Kubow, K. E., Li, Z., Jia, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17279-1 · Cited by 91
Deep generative neural network for accurate drug response imputation
Jia, P., Hu, R., Pei, G., Dai, Y., Wang, Y., & Zhao, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-21997-5 · Cited by 89
Updates in IDH-Wildtype Glioblastoma
Melhem, J. M., Detsky, J. S., Lim-Fat, M. J., & Perry, J. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01251-6 · Cited by 101
Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
Cruz, J. V. R., Batista, C., Afonso, B. D. H., Alexandre‐Moreira, M. S., Dubois, L. G., Pontes, B., Moura‐Neto, V., & Mendes, F. A. (2022) · Cancers · doi:10.3390/cancers14133203 · Cited by 92
Delfanti, R. L., Piccioni, D. E., Handwerker, J., Bahrami, N., Krishnan, A., Karunamuni, R. A., Hattangadi-Gluth, J. A., Seibert, T. M., Srikant, A., Jones, K. A., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2613-7 · Cited by 88
Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy
Branzoli, F., Stefano, A. L. D., Capelle, L., Ottolenghi, C., Valabrègue, R., Deelchand, D. K., Bielle, F., Villa, C., Baussart, B., Lehéricy, S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox214 · Cited by 88
Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype
Patel, S. H., Bansal, A. G., Young, E. B., Batchala, P. P., Patrie, J. T., Lopes, M. B. S., Jain, R., Fadul, C. E., & Schiff, D. (2019) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6102 · Cited by 88
NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview
Pramono, A. A., Rather, G. M., Herman, H., Lestari, K., & Bertino, J. R. (2020) · Biomolecules · doi:10.3390/biom10030358 · Cited by 88
Sperry, J., Condro, M. C., Guo, L., Braas, D., VanderVeer-Harris, N., Kim, K. K. O., Pope, W. B., Divakaruni, A. S., Lai, A., Christofk, H. R., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101453 · Cited by 88
Danussi, C., Bose, P., Parthasarathy, P. T., Silberman, P. C., Arnam, J. S. V., Vitucci, M., Tang, O. Y., Heguy, A., Wang, Y., Chan, T. A.-T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03476-6 · Cited by 91
Mu, L., Long, Y., Yang, C., Jin, L., Tao, H., Ge, H., Chang, Y. E., Karachi, A., Kubilis, P. S., Leon, G. D., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00082 · Cited by 91
Advances in Research of Adult Gliomas
Finch, A., Solomou, G., Wykes, V., Pohl, U., Bardella, C., & Watts, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020924 · Cited by 91
A serum-based DNA methylation assay provides accurate detection of glioma
Sabedot, T. S., Malta, T. M., Snyder, J., Nelson, K. K., Wells, M., deCarvalho, A. C., Mukherjee, A., Chitale, D. A., Mosella, M. S., Sokolov, A., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab023 · Cited by 87
Explainable Artificial Intelligence for Human-Machine Interaction in Brain Tumor Localization
Esmaeili, M., Vettukattil, R., Banitalebi, H., Krogh, N. R., & Geitung, J. T. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111213 · Cited by 90
Bao, J.-H., Lu, W., Duan, H., Ye, Y.-Q., Li, J., Liao, W., Li, Y., & Sun, Y.-P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933973 · Cited by 88
MRI radiomics analysis of molecular alterations in low-grade gliomas
Shofty, B., Artzi, M., Bashat, D. B., Liberman, G., Haim, O., Kashanian, A., Bokstein, F., Blumenthal, D. T., Ram, Z., & Shahar, T. (2017) · International Journal of Computer Assisted Radiology and Surgery · doi:10.1007/s11548-017-1691-5 · Cited by 86
Bady, P., Kurscheid, S., Delorenzi, M., Gorlia, T., van den Bent, M. J., Hoang‐Xuan, K., Vauléon, É., Gijtenbeek, A., Enting, R. H., Thiessen, B. A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1810-6 · Cited by 87
Ash, J. T., Darnell, G., Munro, D. B., & Engelhardt, B. E. (2021) · Nature Communications · doi:10.1038/s41467-021-21727-x · Cited by 90
Extracellular Vesicles in Brain Tumor Progression
D’Asti, E., Chennakrishnaiah, S., Lee, T. H., & Rak, J. W. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0296-1 · Cited by 91
Chen, F., Zhang, Y., Gibbons, D. L., Deneen, B., Kwiatkowski, D. J., Ittmann, M., & Creighton, C. J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3378 · Cited by 87
Ainscough, B. J., Barnell, E. K., Ronning, P., Campbell, K. M., Wagner, A. H., Fehniger, T. A., Dunn, G. P., Uppaluri, R., Govindan, R., Rohan, T. E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0257-y · Cited by 87
Updates in prognostic markers for gliomas
Aquilanti, E., Miller, J. J., Santagata, S., Cahill, D. P., & Brastianos, P. K. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy158 · Cited by 88
Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy
Branzoli, F., Pontoizeau, C., Tchara, L., Stefano, A. L. D., Kamoun, A., Deelchand, D. K., Valabrègue, R., Lehéricy, S., Sanson, M., Ottolenghi, C., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz031 · Cited by 86
Use of big data in drug development for precision medicine: an update
Qian, T., Zhu, S., & Hoshida, Y. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1617632 · Cited by 87
A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration
Chiang, J., Harreld, J. H., Tinkle, C. L., Moreira, D. C., Li, X., Acharya, S., Qaddoumi, I. A., & Ellison, D. W. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02081-1 · Cited by 85
Infratentorial IDH-mutant astrocytoma is a distinct subtype
Banan, R., Stichel, D., Bleck, A. C., Hong, B., Lehmann, U., Suwala, A. K., Reinhardt, A., Schrimpf, D., Buslei, R., Stadelmann, C., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02194-y · Cited by 85
Molecular Pathology of Gliomas
Galbraith, K., & Snuderl, M. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.003 · Cited by 83
Whole-Tumor Histogram Analysis of Multiple Diffusion Metrics for Glioma Genotyping
Gao, A., Zhang, H., Yan, X., Wang, S., Chen, Q., Gao, E., Qi, J., Bai, J., Zhang, Y., & Cheng, J. (2021) · Radiology · doi:10.1148/radiol.210820 · Cited by 85
Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6
Park, E., Kim, N., Ficarro, S. B., Zhang, Y., Lee, B. I., Cho, A., Kim, K., Park, A. K.-J., Park, W., Murray, B. A., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3074 · Cited by 85
Suchorska, B., Giese, A., Biczok, A., Unterrainer, M., Weller, M., Drexler, M., Bartenstein, P., Schüller, U., Tonn, J., & Albert, N. L. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox153 · Cited by 84
World Health Organization 2016 Classification of Central Nervous System Tumors
Diamandis, P., & Aldape, K. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.04.003 · Cited by 84
The master regulator FUBP1: its emerging role in normal cell function and malignant development
Debaize, L., & Troadec, M. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2933-6 · Cited by 86
Kavouridis, V. K., Boaro, A., Dorr, J., Cho, E. Y., Iorgulescu, J. B., Reardon, D. A., Arnaout, O. M., & Smith, T. R. (2019) · Journal of neurosurgery · doi:10.3171/2019.6.jns19972 · Cited by 84
Mathur, R., Zhang, Y., Grimmer, M., Hong, C., Zhang, M., Bollam, S., Petrecca, K., Clarke, J. L., Berger, M. S., Phillips, J. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa059 · Cited by 85
Garrett, M. C., Sperry, J., Braas, D., Yan, W., Le, T. M., Mottahedeh, J., Ludwig, K., Eskin, A., Qin, Y., Levy, R., et al. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0177-4 · Cited by 86
The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation
Weissmann, S., Cloos, P. A., Sidoli, S., Jensen, O. N., Pollard, S. M., & Helin, K. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0342 · Cited by 83
CIC protein instability contributes to tumorigenesis in glioblastoma
Bunda, S., Heir, P., Metcalf, J. L., Li, A. S. C., Agnihotri, S., Pusch, S., Mamatjan, Y., Li, M., Burrell, K. E., Mansouri, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08087-9 · Cited by 84
A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery
Tan, Y. Q., Zhang, S., Wei, J., Dong, D., Wang, X., Yang, G., Tian, J., & Zhang, H. (2019) · European Radiology · doi:10.1007/s00330-019-06056-4 · Cited by 83
IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?
Kayabölen, A., Yilmaz, E., & Onder, T. B. (2021) · Biomedicines · doi:10.3390/biomedicines9070799 · Cited by 88
Total copy number variation as a prognostic factor in adult astrocytoma subtypes
Mirchia, K., Sathe, A. A., Walker, J. M., Fudym, Y., Galbraith, K., Viapiano, M. S., Corona, R. J., Snuderl, M., Xing, C., Hatanpaa, K. J., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0746-y · Cited by 82
Friend or foe—IDH1 mutations in glioma 10 years on
Huang, L. E. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz134 · Cited by 84
Novel IDH1-Targeted Glioma Therapies
Karpel‐Massler, G., Nguyen, T. T. T., Shang, E., & Siegelin, M. D. (2019) · CNS Drugs · doi:10.1007/s40263-019-00684-6 · Cited by 82
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy
Khouzam, R. A., Venkatesh, G. H., Zaarour, R. F., Chamseddine, A. N., Francis, A., Buart, S., Terry, S., & Chouaïb, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.003 · Cited by 84
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications
Mohamed, E., Kumar, A., Zhang, Y., Wang, A. S., Chen, K. Y., Lim, Y., Shai, A., Taylor, J. W., Clarke, J. L., Hilz, S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac064 · Cited by 83
Vision transformer-based weakly supervised histopathological image analysis of primary brain tumors
Li, Z., Cong, Y., Chen, X., Qi, J., Sun, J., Yan, T., Yang, H., Liu, J., Lu, E., Wang, L., et al. (2023) · iScience · doi:10.1016/j.isci.2022.105872 · Cited by 82
Schmassmann, P., Roux, J., Buck, A., Tatari, N., Hogan, S. A., Wang, J., Mantuano, N. R., Wieboldt, R., Lee, S., Snijder, B., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf5302 · Cited by 82
Fast clustering using adaptive density peak detection
Wang, X.-F., & Xu, Y. (2015) · Statistical Methods in Medical Research · doi:10.1177/0962280215609948 · Cited by 81
Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis
Reon, B. J., Anaya, J., Zhang, Y., Mandell, J. W., Purow, B. W., Abounader, R., & Dutta, A. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002192 · Cited by 80
Zhang, Y., Yang, L., Kucherlapati, M. H., Chen, F., Hadjipanayis, A. G., Pantazi, A., Bristow, C. A., Lee, E. A., Mahadeshwar, H. S., Tang, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.025 · Cited by 84
Myxoid glioneuronal tumor, PDGFRA p.K385‐mutant: clinical, radiologic, and histopathologic features
Lucas, C. G., Villanueva-Meyer, J. E., Whipple, N. S., Bush, N. A. O., Cooney, T. M., Chang, S. M., McDermott, M. W., Berger, M. S., Cham, E. M., Sun, P. P., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12797 · Cited by 80
Tumor mutational burden is associated with poor outcomes in diffuse glioma
Wang, L., Ge, J., Yang, L., Shi, Y., Luo, Y., Tan, Y., Liang, M., Deng, S., Zhang, X., Wang, W., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6658-1 · Cited by 79
Biomarker-driven diagnosis of diffuse gliomas
Appin, C., & Brat, D. J. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.002 · Cited by 84
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- Emory University (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2481-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4530011
- OpenAlex
- W1812256879
- Cited by
- 3,148
- References
- 54
- Citations by year
- 2026: 139 · 2025: 196 · 2024: 248 · 2023: 282 · 2022: 371 · 2021: 341 · 2020: 366 · 2019: 314 · 2018: 311 · 2017: 284 · 2016: 226 · 2015: 60
- FWCI
- 164.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, U54HG007990)
- National Cancer Institute (U24CA194362, U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, U24CA143858, U24CA126543, U24CA144025, U24CA126563, U01CA168394, U24CA143866, U24CA143883, U24CA143845, U24CA126544, R01CA163722, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA008748, P30CA016672, U24CA143731)
- National Institute of Neurological Disorders and Stroke (R01NS081125)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioma molecular subtypes, IDH mutation, 1p/19q codeletion, TP53 mutation, TERT promoter mutation, NOTCH1 mutation, CIC mutation, glioblastoma, prognostic factors, DNA methylation, DNA copy number, gene expression, microRNA expression
- MeSH terms
- Adolescent, Adult, Aged, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, DNA, Neoplasm, Female, Glioblastoma, Glioma, Humans, Male, Middle Aged, Mutation, Signal Transduction, Cluster Analysis, Proportional Hazards Models, Genes, p53, Sequence Analysis, DNA, Kaplan-Meier Estimate, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
